{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:12:28Z","timestamp":1751904748662,"version":"3.37.3"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["75F40120F19003","HHSF223201810022I"],"award-info":[{"award-number":["75F40120F19003","HHSF223201810022I"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.vaccine.2024.02.017","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:45:34Z","timestamp":1708577134000},"page":"2004-2010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017\u20132020"],"prefix":"10.1016","volume":"42","author":[{"given":"Patricia C.","family":"Lloyd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-6262","authenticated-orcid":false,"given":"Bradley","family":"Lufkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6502-5212","authenticated-orcid":false,"given":"Keran","family":"Moll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel P.","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl N.","family":"McMahill-Walraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Beachler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Kelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-0648","authenticated-orcid":false,"given":"Shayan","family":"Hobbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandace L.","family":"Amend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djeneba Audrey","family":"Djibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanlai","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Shoaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minya","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-1631","authenticated-orcid":false,"given":"Alex","family":"Secora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy Ke","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2392-0494","authenticated-orcid":false,"given":"Lisa","family":"Kowarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoganand","family":"Chillarige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Forshee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-7450","authenticated-orcid":false,"given":"Stella","family":"Muthuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"MaCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.02.017_b0005","unstructured":"Chen RT, Monash JB. Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS). Brighton Collaboration; 2021."},{"key":"10.1016\/j.vaccine.2024.02.017_b0010","doi-asserted-by":"crossref","unstructured":"See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26. COV2. S vaccination, March 2 to April 21, 2021. JAMA. 2021; 325: 2448\u201356.","DOI":"10.1001\/jama.2021.7517"},{"key":"10.1016\/j.vaccine.2024.02.017_b0015","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2023.09.062","article-title":"Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada","volume":"41","author":"Procter","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.017_b0020","doi-asserted-by":"crossref","unstructured":"Burn E, Li X, Kostka K, Stewart HM, Reich C, Seager S, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID\u201019 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf 2022; 31: 495\u2013510.","DOI":"10.1002\/pds.5419"},{"key":"10.1016\/j.vaccine.2024.02.017_b0025","doi-asserted-by":"crossref","unstructured":"Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. bmj. 2021; 373.","DOI":"10.1101\/2021.03.25.21254315"},{"key":"10.1016\/j.vaccine.2024.02.017_b0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination\u2014United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.02.017_b0035","doi-asserted-by":"crossref","unstructured":"Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. bmj. 2021; 373.","DOI":"10.1136\/bmj.n1114"},{"key":"10.1016\/j.vaccine.2024.02.017_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12682","article-title":"Epidemiology of cerebral venous sinus thrombosis and cerebral venous sinus thrombosis with thrombocytopenia in the United States, 2018 and 2019","volume":"6","author":"Payne","year":"2022","journal-title":"Res Practice Thrombosis Haemostasis"},{"key":"10.1016\/j.vaccine.2024.02.017_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting","author":"Barda","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.02.017_b0050","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","article-title":"Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination","volume":"10","author":"Soboleva","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.02.017_b0055","unstructured":"Liu Y, Goh CH, Shen D, Huang K-C, Qiu H, Luo M, et al. Estimating the incidence of co-occurring thrombosis and thrombocytopenia in a healthcare database. 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). Copenhagen, Denmark; 2022."},{"key":"10.1016\/j.vaccine.2024.02.017_b0060","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020","author":"Moll","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.017_b0065","unstructured":"Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring Protocol; 2021."},{"key":"10.1016\/j.vaccine.2024.02.017_b0070","unstructured":"Center for Biologics Evaluation and Research Office of Biostatistics and Epidemiology Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring: Protocol Addendum; 2021."},{"key":"10.1016\/j.vaccine.2024.02.017_b0075","doi-asserted-by":"crossref","unstructured":"Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. bmj. 2021; 374.","DOI":"10.1136\/bmj.n1931"},{"key":"10.1016\/j.vaccine.2024.02.017_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063645","article-title":"Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic","volume":"13","author":"M\u00fcllerov\u00e1","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.02.017_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101650","article-title":"Hypoxia and hemorheological properties in older individuals","author":"Raberin","year":"2022","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.vaccine.2024.02.017_b0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","article-title":"Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases-an ACCESS cohort study","volume":"41","author":"Willame","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.02.017_b0095","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis","volume":"29","author":"Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.02.017_b0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.10478","article-title":"Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19)","volume":"3","author":"Nahum","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.02.017_b0105","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): update from the Advisory Committee on Immunization Practices\u2014United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"Morbidity Mortality Weekly Report"},{"key":"10.1016\/j.vaccine.2024.02.017_b0110","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","article-title":"Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis","volume":"398","author":"Bhuyan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.02.017_b0115","first-page":"1","article-title":"Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study","author":"Shoaibi","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2024.02.017_b0120","unstructured":"US Food and Drug Administration. Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine."},{"key":"10.1016\/j.vaccine.2024.02.017_b0125","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:40:36Z","timestamp":1714992036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0264410X24001646"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017\u20132020","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}